Cytosorbents’ (CTSO) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a $1.00 price objective on the medical research company’s stock.

Several other analysts have also weighed in on CTSO. StockNews.com began coverage on shares of Cytosorbents in a research note on Sunday. They set a “hold” rating for the company. EF Hutton Acquisition Co. I upgraded shares of Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th.

Cytosorbents Stock Down 4.5 %

NASDAQ:CTSO opened at $0.93 on Monday. The stock has a 50-day simple moving average of $1.13 and a 200 day simple moving average of $1.01. Cytosorbents has a one year low of $0.70 and a one year high of $2.15. The company has a market capitalization of $50.63 million, a price-to-earnings ratio of -2.57 and a beta of 0.56. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.71 and a current ratio of 1.97.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The business had revenue of $9.89 million during the quarter, compared to the consensus estimate of $9.73 million. During the same period in the previous year, the business earned ($0.14) EPS. Sell-side analysts predict that Cytosorbents will post -0.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds have recently made changes to their positions in the business. Sargent Investment Group LLC grew its stake in shares of Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after purchasing an additional 192,747 shares in the last quarter. Atomi Financial Group Inc. bought a new position in Cytosorbents in the 3rd quarter valued at about $51,000. CM Management LLC increased its stake in Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after buying an additional 25,000 shares during the period. Finally, Avenir Corp raised its position in shares of Cytosorbents by 4.0% during the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after buying an additional 121,294 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.